X0609 4 2026-08-13 0000907654 Oruka Therapeutics, Inc. ORKA 0002033974 Agarwal Arjun false C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100 MENLO PARK CA 94025 0 1 0 0 Senior Vice President, Finance 1 Common Stock 2026-08-13 4 M 0 8542 12.5 A 23854 D Common Stock 2026-08-13 4 M 0 1458 34.39 A 25312 D Common Stock 2026-08-13 4 S 0 2100 104.6734 D 23212 D Common Stock 2026-08-13 4 S 0 2132 105.5716 D 21080 D Common Stock 2026-08-13 4 S 0 1268 106.6255 D 19812 D Common Stock 2026-08-13 4 S 0 2142 107.7138 D 17670 D Common Stock 2026-08-13 4 S 0 2358 108.4628 D 15312 D Employee Stock Option (right to buy) 12.5 2026-08-13 4 M 0 8542 0 D 2035-01-21 Common Stock 8542 92917 D Employee Stock Option (right to buy) 34.39 2026-08-13 4 M 0 1458 0 D 2036-01-22 Common Stock 1458 59792 D These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.05 to $104.99, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.11 to $106.08, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.11 to $107.07, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.20 to $108.19, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.24 to $108.71, inclusive. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. /s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal 2026-08-14